Hodgkin lymphoma: A review and update on recent progress (Q47807176)

5 February 2018

http://europepmc.org/abstract/MED/29194581

review article

1 reference

title

Hodgkin lymphoma: A review and update on recent progress (English)

1 reference

5 February 2018

http://europepmc.org/abstract/MED/29194581

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Richard F Ambinder

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

1 December 2017

1 reference

5 February 2018

http://europepmc.org/abstract/MED/29194581

published in

CA

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

116-132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

On Some Morbid Appearances of the Absorbent Glands and Spleen

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

21 January 2018

Cancer Statistics, 2017.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Reevaluation of prognostic significance of symptoms in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Toxicities of Immunotherapy for the Practitioner

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Managing immune checkpoint-blocking antibody side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Breast cancer after treatment of Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Cardiac side-effects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Thyroid Diseases after Treatment of Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Fertility preservation after chemotherapy for Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Characteristics of Hodgkin's Lymphoma after Infectious Mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5842098

Hodgkin disease survival in Europe and the U.S

2 November 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21438

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

21 January 2018

1 reference

12 December 2020

Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas

1 reference

12 December 2020

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1 reference

12 December 2020

Evidence for an orderly progression in the spread of Hodgkin's disease

1 reference

12 December 2020

Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials

1 reference

12 December 2020

Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease

1 reference

12 December 2020

High risk of breast carcinoma after irradiation of young women with Hodgkin's disease

1 reference

12 December 2020

Long-term follow-up of Hodgkin's disease trial

1 reference

12 December 2020

Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages

1 reference

12 December 2020

Long-term cause-specific mortality of patients treated for Hodgkin's disease

1 reference

12 December 2020

The Radical Radiotherapy of Regionally Localized Hodgkin's Disease

1 reference

12 December 2020

Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials

1 reference

12 December 2020

Late cardiotoxicity after treatment for Hodgkin lymphoma

1 reference

12 December 2020

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

1 reference

12 December 2020

Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003

1 reference

12 December 2020

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

1 reference

12 December 2020

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

1 reference

12 December 2020

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis

1 reference

12 December 2020

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

1 reference

12 December 2020

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

1 reference

12 December 2020

Minimizing Cardiac Risks With Contemporary Radiation Therapy for Hodgkin Lymphoma

1 reference

12 December 2020

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

1 reference

12 December 2020

Identifiers

DOI

10.3322/CAAC.21438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29194581%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference